LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Recombinant Antigen-Based ELISA Evaluated for Syphilis

By LabMedica International staff writers
Posted on 28 Aug 2013
Print article
Image: Photomicrograph of Treponema pallidum (Photo courtesy of Susan Lindsley).
Image: Photomicrograph of Treponema pallidum (Photo courtesy of Susan Lindsley).
The diagnostic performance of the latest screening enzyme-linked immunosorbent assay (ELISA) for syphilis has been compared with the currently used treponemal tests.

The etiological agent of syphilis, Treponema pallidum, cannot be cultured and there is no single optimal alternative test. Serological testing is the most frequently used approach in laboratory diagnosis of the disease.

Scientists at Sekisui Virotech (Rüsselsheim, Germany) compared their Treponema pallidum Screen ELISA with standard tests. These tests included the fluorescent treponemal antibody absorption (FTA-ABS, Zeus Scientific; Branchburg, NJ, USA) test, which is an indirect fluorescent antibody technique; the T. pallidum particle agglutination (TPPA, Fujirebio; Hoofddorp, the Netherlands) test, which is a qualitative assay for the detection of antibodies to T. pallidum in serum or plasma. The most relevant test used for comparison was the Trep-Sure ELISA (Phoenix Bio-Tech Corporation; Mississauga, ON, Canada).

To establish the sensitivity and specificity of the Virotech Screen, 421 serum samples from different panels of infected and non-infected patients, sera from seronegative pregnant women as well as international syphilis standard sera and panels were tested. In comparison to combined TPPA/FTA-abs tests, Phoenix Trep-Sure and Virotech Screen demonstrated a sensitivity of 100% and a specificity of 93.9% and 98.3%, respectively.

All samples of a well-defined syphilis serum panel were correctly identified by the Virotech test, whereas the Phoenix test identified two Treponema negative samples as equivocal. The Trep Sure test is approved by the US Food and Drug Administration (FDA; Silver Springs, MD, USA). Results of both ELISAs highly correlated with TPPA negative and positive samples. The analytical sensitivity of the Virotech Screen with international standards was determined at 0.02 IU/mL and 0.03 IU/mL, and was slightly superior to the Phoenix Trep-Sure.

The authors concluded that the Virotech Screen ELISA demonstrated good diagnostic sensitivity and specificity when evaluated as a screening test for syphilis among various patient populations, including samples with increased rates of false positive nontreponemal test results. The Virotech ELISA may be used in automatic analyzers as an alternative to the manual TPPA. However, the use of a confirmatory test remains a must in order to avoid false-positive results. The study was published in the May/June, 2013 issue of the journal Clinical Laboratory.

Related Links:

Sekisui Virotech
Zeus Scientific
Fujirebio


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.